Does Rallies show 13F holders for PTGX?

Yes. Rallies tracks hedge fund and 13F ownership data for PTGX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PTGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PTGX. It does not provide personalized investment advice.

PTGX (Protagonist Therapeutics, Inc) Stock Analysis - Hedge Fund Holdings

Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of May 21, 2026, PTGX trades at $100.71 with a market cap of $6.48B and a P/E ratio of -55.44. PTGX moved +2.53% today. Year to date, PTGX is +19.84%; over the trailing twelve months it is +116.43%. Its 52-week range spans $33.31 to $107.84. Analyst consensus is strong buy with an average price target of $117.00. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PTGX stock?

Hedge funds tracked by Rallies that own PTGX include Farallon Capital, Mangrove Partners, Duquesne Family, Panagora Asset, and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Protagonist Therapeutics, Inc.

PTGX Key Metrics

Key financial metrics for PTGX
Metric	Value
Price	$100.71
Market Cap	$6.48B
P/E Ratio	-55.44
EPS	$-1.81
Dividend Yield	0.00%
52-Week High	$107.84
52-Week Low	$33.31
Volume	295.34K
Avg Volume	0
Revenue (TTM)	$74.06M
Net Income	$-114.71M
Gross Margin	0.00%

Top Hedge Funds Holding PTGX

Farallon Capital holds 6.35M shares of PTGX, changed +3.33% as of Mar 31, 2026.
Mangrove Partners holds 478.41K shares of PTGX, changed +21.00% as of Sep 30, 2025.
Duquesne Family holds 159.70K shares of PTGX, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 116.61K shares of PTGX, changed -7.00% as of Mar 31, 2026.
Soros Fund holds 100.00K shares of PTGX, changed +0.00% as of Dec 31, 2025.

Latest PTGX News

Protagonist Therapeutics jumps as Q1 profit and rusfertide Priority Review refocus attention — May 6, 2026
Protagonist Secures $200M Rusfertide Opt-Out Fee and $50M ICOTYDE Milestone — May 5, 2026
PTGX climbs as traders rotate into catalyst-driven biotech ahead of early-May results — Apr 28, 2026
Protagonist Exercises U.S. Rusfertide Opt-Out for $475M Upfront and $975M Milestones — Apr 28, 2026
PTGX slides 3% as post-rally profit-taking meets fresh insider-selling overhang — Apr 24, 2026

Recent PTGX Insider Trades

PATEL DINESH V PH D sold 75.00K (~$7.51M) on May 12, 2026.
PATEL DINESH V PH D sold 75.00K (~$7.51M) on May 12, 2026.
Giraudo Bryan sold 6.00K (~$600.00K) on May 8, 2026.

PTGX Analyst Consensus

11 analysts cover PTGX: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.00.

Common questions about PTGX

Who owns PTGX stock?: Hedge funds tracked by Rallies that own PTGX include Farallon Capital, Mangrove Partners, Duquesne Family, Panagora Asset, and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Protagonist Therapeutics, Inc.
Does Rallies show 13F holders for PTGX?: Yes. Rallies tracks hedge fund and 13F ownership data for PTGX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PTGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PTGX. It does not provide personalized investment advice.